DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; HNSCC, head and neck squamous cell cancer; MIBC, muscle-invasive bladder cancer.
DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; HNSCC, head and neck squamous cell cancer; MIBC, muscle-invasive bladder cancer.
LUMINOS-103 (NCT04690699) is a multicenter, open-label, single-arm phase 1/2 basket study investigating the efficacy and safety of lerapolturev in several solid tumor types. The study enrolled its first patient in October 2021 and is ongoing at a rapidly expanding list of US sites.
The phase 1 part of each study will include approximately 6 patients with each tumor type, who will be evaluated for safety. Once approved by the DSMC, the phase 2 part of the study will enroll approximately 25 patients in each cohort.
Please contact us or email LUMINOS-103@istarioncology.com.